CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by an educational grant from Amgen.
Target Audience: The intended audience for this activity is internists and other health care professionals involved in the treatment of patients with dyslipidemia.
Learning Objectives: Upon successful completion of this activty, participants should be better able to:
- Review the latest clinical evidence regarding the impact of PCSK9 inhibitors and very low LDL-C on patient outcomes.
- Utilize PCSK9 inhibitors in patients who may benefit in accordance with the latest clinical evidence and recommendations.
- Utilize strategies to increase the number of eligible patients who obtain access to PCSK9 inhibitors.
Activity Chair:
James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
Lipidology & Cardiovascular Disease Prevention
Clinical Assistant Professor of Medicine
NYU Medical School & NYU Center for CV Prevention
Director, Bellevue Hospital Lipid Clinic
New York, NY
Faculty:
Michael H. Davidson, MD, FACC, FACP, FNLA
Director of the Lipid Clinic
The University of Chicago
Pritzker School of Medicine
Chicago, IL
Daniel E. Soffer, MD, FNLA, FACP
Clinical Associate Professor of Medicine
University of Pennsylvania Internal Medicine and Preventive Cardiology
University of Pennsylvania Health System
Philadelphia, PA
Reviewers:
Dinesh Kalra, MD, FACC
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP (Recertification review on 5/31/2019)
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material was originally approved for 1 year from the date of original release, May 29, 2018 to May 28, 2019. It has since been recertified for an additional year and will now expire on May 28, 2020.
How to Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty report the following relationships, which are accurate at the time of original content release (May 29, 2018):
Michael H. Davidson, MD, FACC, FACP, FNLA
Consulting Fee: Amgen, Novo Nordisk, Regeneron, Sanofi
Speakers Bureau: Amgen, Novo Nordisk, Regeneron, Sanofi
Daniel E. Soffer, MD, FNLA, FACP
Consulting Fee: Akcea
Speakers Bureau: Akcea
Contracted Research: Amgen, AstraZeneca, Esperion, Ionis/Akcea, Kowa, Novartis, Sanofi, Regeneron, Regenix/NIH
James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA
Consulting Fee: Amarin, Amgen
Speakers Bureau: Aegerion, Akcea, Alexion, Amarin, Amgen, Kastle, Regeneron, Sanofi
Contracted Research: Aegerion, Pfizer
Advisory Boards: Aegerion, Akcea, Amgen, Kastle, Regeneron, Sanofi
Reviewers report the following relationship(s):
Dinesh Kalra, MD, FACC
No relevant financial relationships to disclose.
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2018 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com